Search
LuLym-T
go.drugbank.com/drugs/DB17405ExperimentalLuLym-T is an investigational autologous immune cell therapy consisting of activated T Lymphocytes. Developed by Lukas Biomedical, Inc., it is currently being investigated in hepatocellular carcinoma.
Synonyms: Autologous Activated T Lymphocytes (ATL), LuLym-TENTR-601-44
go.drugbank.com/drugs/DB17836InvestigationalENTR-601-44 is an exon 44 skipping phosphorodiamidate morpholino oligonucleotide (PMO). Developed by Entrada Therapeutics, it was investigated for the treatment of Duchenne muscular dystrophy.[L46641]
PAS-004
go.drugbank.com/drugs/DB18611InvestigationalPAS-004 is an allosteric MEK 1/2 inhibitor being developed by Pasithea Therapeutics. It is being investigated for the treatment of neurofibromatosis 1 and Noonan syndrome.
Pentetrazol
go.drugbank.com/drugs/DB13415ApprovedWithdrawnPentetrazol, also known as pentylenetetrazole, is a gamma-aminobutyric acid type A (GABA<sub>A</sub>) receptor antagonist that was approved by the FDA until 1982.[A254437]
Adecatumumab
go.drugbank.com/drugs/DB05006InvestigationalEpCAM (CD326) is a cell surface protein that is frequently expressed at high level on most solid tumor types, including prostate, breast, colon, gastric, ovarian, pancreatic and lung cancer. … Adecatumumab is a recombinant human monoclonal antibody of the IgG1 subclass with a binding specificity to epithelial cell adhesion molecule (EpCAM).
NUC B1000
go.drugbank.com/drugs/DB05242ExperimentalNUC B1000 is an expressed interfering RNA (eiRNA)- based product consisting of a plasmid DNA construct designed to produce four short interfering RNA (siRNA) molecules, formulated with a proprietary cationic-lipid … the RNAi response against a targeted disease causing gene.
Macadamia seed oil glycereth-8 esters
go.drugbank.com/drugs/DB14318InvestigationalMacadamia seed oil glycereth-8 esters is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.
Selodenoson
go.drugbank.com/drugs/DB16325InvestigationalSelodenoson is under investigation in clinical trial NCT00040001 (Safety and Efficacy Study of an A1-adenosine Receptor Agonist to Slow Heart Rate in Atrial Fibrillation).
ALM201
go.drugbank.com/drugs/DB17206InvestigationalALM201 is an anti-angiogenic synthetic peptide identified from the endogenous human protein, FKBPL. It is being investigated in the treatment of various cancers.[A254556]